Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Harnessing extracellular vesicles for ischemic stroke management

Haroon K., Yu J., Li R., Ren C., Li Z.

Narrative Review on Stroke Research, Neuroinflammation, published in Regen Biomater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Regen Biomater (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41994598
PMCID
PMC13082904
DOI
10.1093/rb/rbag038

Abstract (original English)

Extracellular vesicles (EVs) are versatile, cell-derived complexes that serve as a complete package of biologically important molecules, released during both normal and pathological processes. With rapid advancements in EVs research, there has been a shift in its therapeutic applications, clinical development and commercialization. EVs have been extensively studied for their potential to mitigate ischemic stroke pathological mechanisms, such as excitotoxicity, immune response, blood-brain barrier (BBB) dysfunction, neuroinflammation and apoptosis. EVs' innate ability to protect molecular cargo (proteins, DNA or RNA) from enzymatic degradation, their natural ability to traverse BBB, high cargo-loading efficiency and superior biocompatibility make them ideal candidates for targeted drug delivery systems in ischemic stroke. Their presence in most biofluids and changes in their contents during disease conditions, support investigation of EVs as promising minimally invasive biomarkers for the early diagnosis and treatment monitoring of ischemic stroke. Moreover, EVs in combination with other therapeutic agents have considerable potential for clinical translation. This perspective provides a comprehensive overview of current literature on EV-based systems in stroke management, highlighting their role as standalone therapeutics, presenting opportunities for cargo delivery, biomarkers

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research